The immunogens being tested in IAVI G002 were developed by scientific teams at IAVI and Scripps Research and will be delivered via Moderna's mRNA technology
This will evaluate the immunogenicity, safety, and reactogenicity of a single booster dose in adults aged 18 years and older
The company develops sustainable botanical materials for agricultural and pharmaceutical applications
_256_384.jpg)
The oversubscribed round was led by New York-based HOF Capital and welcomed new investors including Headline, East Ventures, MS&AD Ventures, DG Daiwa Ventures, Pioneer Fund, as well as existing investor Insignia Ventures Partners
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
Philips expands remote cardiac monitoring portfolio with patch-based, clinical-grade ECG designed to improve patient recruitment, compliance and retention by reducing need for site visits during clinical trials
Leading brands like Sporlac, Lobun, Oxalo, Pubergen, Nano-leo and Gynogen will now be part of the JBCPL franchise
Optimized for pharma/biopharma to deliver a deeper understanding of cellular function
Studies show significant reduction in pain and improved quality of life for patients treated with spinal cord stimulation compared to medication management alone
Companies plan to commercialize breath-based detection of lung infection and transplant rejection
Subscribe To Our Newsletter & Stay Updated
